PROPHYLACTIC PLATELET DOSE STRATEGY TO PREVENT BLEEDING IN THROMBOCYTOPENIA

预防血小板减少症出血的预防性血小板剂量策略

• 批准号: 7604833
• 负责人: RONALD G STRAUSS
• 金额: $ 0.03万
• 依托单位: UNIVERSITY OF IOWA
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-03-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7604833
• 关键词: Blood Platelets; Categories; Computer Retrieval of Information on Scientific Projects Database; Cost Analysis; Disease Management; Dose; Erythrocytes; Frequencies; Funding; Grant; Hemorrhage; Hemostatic function; Institution; Numbers; Outcome; Patients; Rate; Research; Research Personnel; Resources; Severities; Source; Thrombocytopenia; Time; Transfusion; United States National Institutes of Health; Upper arm; cost; cost effective; day; experience; prevent; prophylactic

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. As platelet use continues to increase at a rate disproportionately higher than that of red blood cells, it is important to identify the most cost-effective strategies for providing platelet support. Identification and implementation of the most safe and cost effective strategies for providing platelet support is crucial for effective disease management without depleting platelet supplies. The primary objective of this study is to compare the three study arms of high, medium, and lower dose platelet therapy with respect to the percentage of patients experiencing at least one episode of Grade 2 or higher bleeding, as determined by the Platelet Dose Trial Bleeding Scale. Secondary objectives are to compare the three study arms with respect to platelet and hemostasis related outcomes (i.e., platelet utilization rates, frequency of transfusions, days of platelet support, number of days to first Grade 2+ bleeding, highest category of bleeding during time on the study, bleeding severity, etc.). A cost analysis will also be conducted.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目及 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 由于血小板的使用持续以远远高于红细胞的速度增加，因此确定提供血小板支持的最具成本效益的策略非常重要。 确定和实施最安全、最具成本效益的血小板支持策略对于在不耗尽血小板供应的情况下进行有效的疾病管理至关重要。 本研究的主要目的是比较高、中和低剂量血小板治疗的三个研究组，根据血小板剂量试验出血确定的至少经历一次 2 级或以上出血的患者百分比规模。 次要目标是比较三个研究组的血小板和止血相关结果（即血小板利用率、输血频率、血小板支持天数、首次 2 级以上出血的天数、治疗期间出血的最高类别）研究、出血严重程度等）。 还将进行成本分析。